Compugen Ltd. (CGEN)
| Market Cap | 537.33M |
| Revenue (ttm) | 2.00M |
| Net Income (ttm) | -35.73M |
| Shares Out | 83.92M |
| EPS (ttm) | -0.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 339,324 |
| Open | 6.35 |
| Previous Close | 6.46 |
| Day's Range | 6.15 - 6.46 |
| 52-Week Range | 5.76 - 18.75 |
| Beta | 2.31 |
| Analysts | Strong Buy |
| Price Target | 21.33 (+243.0%) |
| Est. Earnings Date | Nov 4, 2021 |
About CGEN
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for Compugen stock is "Strong Buy." The 12-month stock price forecast is 21.33, which is an increase of 242.98% from the latest price.
News
Compugen to Present at the Cantor Global Healthcare Conference
HOLON, Israel, Sept. 14, 2021 /PRNewswire/ -- Compugen Ltd.
Compugen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
HOLON, Israel, Aug. 26, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that ...
This Unknown Biotech Has a Secret Weapon for Outsized Returns
Bio-Rad's equity position in a German pharma company is an asset many investors may not realize.
Compugen's Out-Licensed Lung Cancer Candidate Enters Human Trial
AstraZeneca Plc's (NASDAQ: AZN) bispecific antibody derived from Compugen Ltd's (NASDAQ: CGEN) COM902 will advance into clinical development. AstraZeneca plans to initiate a Phase 1/2 study evaluating ...
Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development
HOLON, Israel , Aug. 19, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced tha...
Why Compugen Stock Is Rising Again Today
Momentum is carrying over from the company's second-quarter update on Wednesday.
Why Compugen Stock Is Jumping Today
Investors were especially interested in the company's pipeline update.
Compugen Reports Second Quarter 2021 Results
HOLON, Israel, July 28, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for...
Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myer...
HOLON, Israel, July 19, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first pat...
Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies
HOLON, Israel , July 15, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery today announced that the first patie...
Compugen to Release Second Quarter 2021 Results on Wednesday, July 28, 2021
HOLON, Israel, July 14, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company wil...
Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study
HOLON, Israel, June 30, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patie...
Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis
HOLON, Israel, June 29, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of ...
Compugen's COM701 Shows Treatment Durability Beyond One Year in Solid Tumor Patients
Compugen Ltd (NASDAQ: CGEN) has announced updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and in a dose-escalation combination study with Bristol-Myers Squib...
Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Mee...
HOLON, Israel, June 8, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, presented updated data from its Phase ...
Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities
HOLON, Israel, June 1, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that members of its s...
Why Compugen Stock Is Jumping Today
Investors liked what the company had to say in its Q1 update.
Compugen Reports First Quarter 2021 Results
HOLON, Israel, May 13, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for ...
Compugen to Participate at SITC's Targets for Cancer Immunotherapy: A Deep Dive Seminar Series
HOLON, Israel, May 11, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that Eran Ophir, Ph.D.
Compugen Announces Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Disco...
HOLON, Israel, May 10, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has expanded...
Compugen to Release First Quarter 2021 Results on Thursday, May 13, 2021
HOLON, Israel, May 3, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will ...
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the American Society of Clinical Oncology 2021 An...
HOLON, Israel, April 29, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it will presen...
Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy
HOLON, Israel, April 27, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of ...
7 Stocks That Could Double by Summer
These seven stocks may be risky, but they also have the potential for big returns -- as all of them are stocks that could double by summer. The post 7 Stocks That Could Double by Summer appeared first o...
Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy
HOLON, Israel, March 9, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of a...